Document is current
Any future updates will be listed below
-
Authors
Lin, Zhi
Long, Fei
Liu, Jiao
Kang, Rui
Klionsky, Daniel J.
Kroemer, Guido
Tang, Daolin
Yang, Minghua
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82400213)
- License Information
-
More Information
Article History
Received: 2 March 2025
Accepted: 18 June 2025
First Online: 23 July 2025
Change Date: 11 February 2026
Change Type: Update
Change Details: The published version was updated as the supplementary materials were out of order and some files were missing.
Declarations
:
: The authors declare no competing interests.
: G.K. has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro, Tollys, and Vascage. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is in the scientific advisory boards of Hevolution, Institut Servier, Longevity Vision Funds and Rejuveron Life Sciences. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. Among these patents, one “Methods for weight reduction” (US11905330B1) is relevant to this study. GK’s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. IM is a consultant of everImmune. GK’s wife, Laurence Zitvogel, has held research contracts with Glaxo Smyth Kline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9 m, Tusk and Roche, was on the on the Board of Directors of Transgene, is a cofounder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. The funders had no role in the design of the study; in the writing of the manuscript, or in the decision to publish the results.
